Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study

Luca Iaccarino(University of Padua), Andrea Doria(University of Padua), Mariele Gatto(University of Padua), Salvatore De Vita(University of Udine), Marta Mosca(University of Pisa), Carlo Salvarani(University of Modena and Reggio Emilia), Lorenzo Emmi, Pier Luigi Meroni(University of Milan), Marcello Govoni(University of Ferrara), G. De Marchi(University of Udine), Maddalena Larosa(University of Padua), Chiara Tani(University of Pisa), Francesca Saccon(University of Padua), Elena Bartoloni(University of Perugia), Giulia Pazzola(Azienda Sanitaria Unità Locale di Reggio Emilia), Laura Andréoli(University of Brescia), Rossella De Angelis(Marche Polytechnic University), Giacomo Emmi(Azienda Ospedaliero-Universitaria Careggi), Anna Chiara Frigo(University of Verona), Roberto Gerli(University of Perugia), Rossella Reggia(Marche Polytechnic University), Maria Gerosa(Istituto Ortopedico Gaetano Pini), Anǵela Tincani(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Andrea Di Matteo(University of Leeds), Margherita Zen(University of Padua), Fulvia Ceccarelli(Sapienza University of Rome), Fabrizio Conti(Policlinico Umberto I), Alessandra Bortoluzzi(University of Ferrara)
Journal of Autoimmunity
September 19, 2017
Cited by 102


Related Papers